Quellen:

  1. Fachinformation Marcumar®, MEDA Pharma GmbH & Co. KG, Bad Homburg. Stand Mai 2015.
  2. Heidbuchel H et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–1507. http://www.ncbi.nlm.nih.gov/pubmed/26324838
  3. Wallin R et al. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 1985; 76: 1879–1884. https://www.ncbi.nlm.nih.gov/pubmed/3932474
  4. Fachinformation Coumadin®. Bristol-Myers Squibb GmbH & Co. KGaA, München. Stand September 2015.
  5. Kirchhof P et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur Heart J 2016: 1609–1678. https://www.ncbi.nlm.nih.gov/pubmed/27567408
  6. Zoni-Berisso M et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213–220. https://www.ncbi.nlm.nih.gov/pubmed/24966695
  7. Lichten C et al. The future of anticoagulation management in atrial fibrillation in Europe. An assessment of today’s challenges with recommendations for the future. Online verfügbar unter: http://www.rand.org/pubs/research_reports/RR1053.html
  8. Herold G. Innere Medizin. Gerd Herold, Köln; 2009.
  9. Deutsche Gesellschaft für Kardiologie. ESC Pocket Guidelines: Leitlinien für das Management von Vorhofflimmern, Stand 2012. http://leitlinien.dgk.org/files/Pocket_Leitlinien_Vorhofflimmern_Update2013.pdf
  10. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4–8. http://www.ncbi.nlm.nih.gov/pubmed/12814979
  11. Reitsma PH et al. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012; 32: 563–568. https://www.ncbi.nlm.nih.gov/pubmed/22345594
  12. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370–372. http://www.ncbi.nlm.nih.gov/pubmed/18296591
  13. Schinzel H et al. Therapie der frischen tiefen Beinvenenthrombose. Dtsch Med Wochenschr 2013; 138: 786–791.
  14. European Society of Cardiology, ESC pocket guidelines: Management der akuten Lungenembolie, Stand 2014. http://leitlinien.dgk.org/files/2015_PLL_Lungenembolie_internet1.pdf
  15. Herdegen T et al. Kurzlehrbuch Pharmakologie und Toxikologie. 3. Auflage, Thieme Verlag; 2013.
  16. Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104. http://www.ncbi.nlm.nih.gov/pubmed/24251359
  17. The Hokusai-VTE investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415. http://www.ncbi.nlm.nih.gov/pubmed/23991658
  18. Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992. http://www.ncbi.nlm.nih.gov/pubmed/21870978
  19. Agnelli G et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808. https://www.ncbi.nlm.nih.gov/pubmed/23808982
  20. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891. http://www.ncbi.nlm.nih.gov/pubmed/21830957
  21. Investigators E et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510. https://www.ncbi.nlm.nih.gov/pubmed/21128814
  22. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151. http://www.ncbi.nlm.nih.gov/pubmed/19717844
  23. Schulman S et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352. https://www.ncbi.nlm.nih.gov/pubmed/19966341
  24. Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962. http://www.ncbi.nlm.nih.gov/pubmed/24315724